Global Blood Therapeutics Inc
Change company Symbol lookup
Select an option...
GBT Global Blood Therapeutics Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
HIIIU Hudson Executive Investment Corp III
PMVP PMV Pharmaceuticals Inc
GER Goldman Sachs MLP and Energy Renaissance Fund
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Closing Price
$67.99
Day's Change
0.02 (0.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
68.04
Day's Low
67.83
Volume
(Light)
Volume:
1,469,191

10-day average volume:
2,952,260
1,469,191
  • Prev Close
    67.97
  • Today's Open
    67.91
  • Day's Range
    67.83-68.04
  • Avg Vol (10-day)
    3.0M
  • Last (time)
    4:00p ET 09/23/22
  • Last (size)
    1
  • 52-Wk Range
    21.65 - 73.02
    LowHigh
  • (06/13/22 - 08/05/22)
    6.89%
  • 75.3%
  • Market Cap
    4.6B
  • Shares Outstanding
    67.5M
  • -5.00
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.5
  • 108.31
  • (% of float 08/31/22)
    10.99

Latest News

September 24, 2022
2:26 pm ET
PR Newswire
September 22, 2022
6:20 pm ET
Accesswire
5:26 pm ET
Globe Newswire
September 21, 2022
10:31 am ET
PR Newswire
September 20, 2022
5:27 pm ET
Globe Newswire
September 16, 2022
12:17 pm ET
PR Newswire
September 15, 2022
6:00 pm ET
Globe Newswire
September 08, 2022
8:00 am ET
Globe Newswire
September 06, 2022
9:30 am ET
PR Newswire
September 02, 2022
3:31 pm ET
PR Newswire
September 01, 2022
9:30 am ET
Accesswire
August 31, 2022
8:39 am ET
Globe Newswire
August 30, 2022
2:32 pm ET
PR Newswire
August 29, 2022
9:00 am ET
PR Newswire
August 27, 2022
7:18 pm ET
Accesswire
August 25, 2022
5:17 pm ET
Globe Newswire
August 24, 2022
8:12 am ET
Globe Newswire
August 23, 2022
10:41 pm ET
PR Newswire
August 22, 2022
9:42 am ET
PR Newswire
August 20, 2022
7:07 pm ET
Accesswire
August 17, 2022
9:01 am ET
Accesswire
August 16, 2022
7:20 pm ET
Accesswire
7:48 am ET
Globe Newswire
August 15, 2022
2:39 pm ET
PR Newswire
9:00 am ET
PR Newswire
August 13, 2022
7:07 pm ET
Accesswire
August 12, 2022
8:06 am ET
MarketWatch
August 11, 2022
12:32 pm ET
Globe Newswire
12:15 am ET
Accesswire
August 10, 2022
8:09 pm ET
Accesswire
5:00 am ET
Accesswire
August 09, 2022
4:48 pm ET
Globe Newswire
1:55 pm ET
PR Newswire
10:45 am ET
Newsfile
7:55 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.